718 918 4026
glenn.fennelly@einstein.yu.edu

Undergraduate:
Dartmouth College

Graduate:
Harvard School of Public Health, MPH in Clinical Effectiveness

Medical School:
New Jersey Medical School- Newark

Awards and Honors:

• 1999 Elizabeth Glaser Pediatric AIDS Foundation Research Grant Award
• 1997 National Foundation for Infectious Diseases Young Investigator Award
• 1991 Connaught Laboratories Pediatric Infectious Disease Fellowship Award
• 1991 The Leo M. Davidoff Society Certificate of Distinction

Research and/or Clinical Interests:

• Scale up of prevention and treatment HIV in high-prevalence resource-limited settings
• Treatment of nosocomial infections
• Vaccines
• Development of a combination pediatric HIV-TB vaccine
• HIV immunopathogenesis in children

Bibliography:

• Ranganathan U, Larsen M, Kim J, Porcelli SA, Jacobs WR, Jr, Fennelly GJ. Recombinant Proapoptotic M. tuberculosis Generates CD8+ T-cell Responses Against Human Immunodeficiency Virus Type 1 Env and M. tuberculosis in Neonatal Mice. Vaccine 2009.
• Bueno SM, González PA, Cautivo KM, Mora JE, Leiva ED, Tobar HE, Fennelly GJ, Eugenin EA, Jacobs WR Jr, Riedel CA, Kalergis AM. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A. 2008 Dec 15.
• Mo Y, Quanquin NM, Fennelly GJ, et al: Genetic alteration of Mycobacterium smegmatis to improve mycobacterium-mediated transfer of plasmid DNA into mammalian cells and DNA immunization. Infect Immun 2007;75):4804-16.
• Raffaelli RM, Paladini M, Fennelly GJ, et al: Child care-associated outbreak of Escherichia coli O157:H7 and hemolytic uremic syndrome. Pediatr Infect Dis J 2007;26:951-3.
• Ballan WM, Vu BA, Fennelly GJ et al: Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol 2007;179:3362-70.
• Mo Y, Quanquin NM, Fennelly GJ, et al: Genetic alteration of Mycobacterium smegmatis to improve mycobacterium-mediated transfer of plasmid DNA into mammalian cells and DNA immunization. Infect Immun 2007;75):4804-16.
• Abadi J, Sprecher E, Fennelly GJ, et al: Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children. J Acquir Immune Defic Syndr 2006;41:298-303.
• Cayabyab MJ, Hovav AH, Fennelly GJ, et al: Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol 2006;80:1645-52.
• Fennelly GJ. And Charles M, Opportunities to prevent mother-to-child transmission (PMTCT) of HIV: Lessons learned in Bronx (New York), Kijabe (Kenya) and Kericho (Kenya). PART I of II. Perspectives From the International Center for Equal Healthcare Access. Medscape May 2006
• Legrand FA, Abadi J, Fennelly GJ, et al: Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS 2005;19:1575-85.
• Vecino WH, Quanquin NM, Fennelly GJ, et al: Mucosal immunization with attenuated Shigella flexneri harboring an influenza hemagglutinin DNA vaccine protects mice against a lethal influenza challenge. Virology 2004;325:192-9.
• Fennelly GJ: Mycobacterium bovis versus Mycobacterium tuberculosis as a cause of acute cervical lymphadenitis without pulmonary disease. Pediatr Infect Dis J 2004;23:590-1.
• Sandberg JK, Fast NM, Fennelly GJ, et al: HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. J Immunol 2003;170:4403-10.
• Eaton EE, Dobrozycski J, Loas R, Laddis D, Fennelly GJ: Nontyphoidal salmonella bacteremia and pneumonia as the initial manifestation of human immunodeficiency virus infection in a four-year-old child. AIDS Patient Care STDS 2002;16:247-50.